Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer of common stock that an officer, Shannon M. Parisotto, has notified for potential resale under Rule 144. The notice lists 2,039 common securities, with UBS Financial Services Inc. acting as broker, and references the NYSE and a date of 08/19/2026.
The filing also lists prior dispositions of CRL common securities by Shannon M. Parisotto during the past three months: 5,046 units on 08/05/2026 and 3,714 units on 08/11/2026, each with stated transaction values. A figure of 47,738,872 common securities is shown for CRL, providing context for the issuer’s total amount of this class.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer for which a holder, Nancy C. Andrews, has filed a notice of proposed sale under Rule 144. The notice covers the potential sale of 573 shares of common stock, with an aggregate market value of 163,305, out of 48,167,730 shares outstanding, through UBS Financial Services Inc., with an approximate sale date of 08/18/2026 following a stock option exercise.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Chief Executive Officer Birgit Girshick exercised stock options for 6,500 shares of common stock on August 11, 2026 at an exercise price of $179.66 per share. The resulting 6,500 common shares were then sold at $279.90 per share on the same date, in a transaction marked as a sale. The company reports that this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 3, 2025. Following these transactions, Girshick has an indirect holding of 43,803 common shares through a revocable trust.
Charles River Laboratories International executive Shannon M. Parisotto, CEVP, Discovery & Safety Assessment, exercised stock options for 3,714 shares of common stock at an exercise price of $179.66 per share on 2026-08-11 and sold the same 3,714 shares at $279.66 per share. The exercise and sale were carried out pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following these transactions, reported indirect holdings include 9,680 shares held by a trust and 28,510 shares held by Karpathos Investments LLC.
Invesco Ltd., a Bermuda-based parent holding company, reports a significant passive ownership position in Charles River Laboratories International, Inc. common stock. Invesco may be deemed to beneficially own 2,984,785 shares, representing 6.2% of the outstanding common stock, held of record by its investment advisory clients.
Invesco has sole voting power over 2,955,113 shares and sole dispositive power over 2,984,785 shares, with no shared voting or dispositive power. The filing notes that no single underlying client has more than 5% economic ownership of Charles River’s common stock; the relevant clients receive dividends and sale proceeds. Subsidiaries involved include Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC.
Charles River Laboratories International, Inc. executive Joseph W. LaPlume, EVP, Corp Strategy & Develop, reported a bona fide gift of 257 shares of common stock on 2026-08-10. The transaction was a disposition made at a reported per-share price of $0.00, leaving him with 31,041 shares of direct ownership afterward.
Charles River Laboratories International director James C. Foster exercised stock options for 28,733 shares of common stock at an exercise price of $179.66 per share on August 10, 2026 and immediately sold 28,733 shares at $275.00 per share. The options, originally exercisable from May 29, 2021 and expiring May 29, 2030, now show 0 derivative shares remaining from this grant. The exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster is reported with indirect holdings of common stock through various trusts and GRATs, including 5,423 shares in a 2024 GRAT, 10,780 shares in a 2025 GRAT, and 20,000 shares in a 2026 GRAT.
CRL reports a planned disposition of common stock under a Rule 144 notice. The reporting shareholder, Shannon M. Parisotto, lists 3,714 shares of common stock to be sold for cash on 08/11/2026, with UBS Financial Services, Inc. as broker. The shares are to be issued through an exercise of stock options.
The filing also notes that during the past three months Parisotto sold 5,046 shares of common stock on 08/05/2026 for total proceeds of $1,327,098.00.
Charles River Laboratories International, Inc. senior vice president of finance and chief accounting officer Michael Gunnar Knell reported option exercises and share sales on 2026-08-06. He exercised stock options covering 2,345 shares of common stock at strike prices of $179.66, $194.12, and $208.44 per share and reported open-market sales totaling 6,645 shares of common stock at prices between $258.53 and $265.17 per share, executed in multiple trades at weighted average prices for several tranches.